Experts present clinical cases of PEComa, discuss approaches to treating patients, and share their perspectives on key clinical trial data that may impact treatment decisions.
EP. 1: Introduction to PEComas
Andrew Folpe, MD, provides an overview of PEComas, including their incidence rate and malignant tumors.
EP. 2: Current Treatment Landscape of PEComas
Elizabeth Davis, MD, explains the current treatment options available for patients with PEComa.
EP. 3: Systemic Therapy in Malignant PEComas
Andrew Wagner, MD, PhD, details his typical treatment approach for systemic therapy in patients with malignant PEComa.
EP. 4: Case 1: Uterine PEComa with a TSC2 Mutation
Dr Elizabeth Davis presents the case of a young woman with a TSC2-mutated uterine PEComa.
EP. 5: The AMPECT Trial: Nab-sirolimus in PEComa
Dr Andrew Wagner shares data from the AMPECT trial investigating the potential role of mTOR inhibitors in PEComa.
EP. 6: Toxicity Management in Patients Receiving mTOR Inhibitors
A discussion on the toxicities associated with mTOR inhibitors and which patients with PEComa would be considered good candidates.
EP. 7: Treatment Options for PEComas After Progression on Nab-Sirolimus
A review of the available treatment options for a patient with PEComa who have disease progression after nab-sirolimus.
EP. 8: Case 2: Hormone Receptor Positive Uterine PEComa
Martee Hensley, MD, presents the case of a post-menopausal woman with a hormone receptor positive malignant uterine PEComa.
EP. 9: Case 3: Retroperitoneal PEComa
Dr Andrew Wagner presents the case of a young man with a retroperitoneal PEComa.
EP. 10: The Future of Research in PEComas
The panel shares future areas of research in malignant PEComa that interest them, and how they see the treatment landscape evolving.
2 Clarke Drive Cranbury, NJ 08512